See today's BioWorld Asia
To read the full story, subscribe or sign in.

GI Innovation licenses GI-101 to Simcere at maximum $796 million

Dec. 3, 2019
By Jihyun Kim
No Comments
HONG KONG – Seoul, South Korea-based GI Innovation Inc. has licensed to Nanjing, Jiangsu-based Simcere Pharmaceutical Co. Ltd. rights to its immunotherapy drug candidate, G1-101, a bispecific CD80/interleukin2 (IL-2) variant fusion protein.
BioWorld Asia Deals and M&A Cancer